EP
GMAB icon

Eudaimonia Partners’s Genmab GMAB Stock Holding History

Eudaimonia Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-417
Closed -$14K – 754
2021
Q1 		$14K Sell
417
-86
-17% -$3.23K ﹤0.01% 1074
2020
Q4 		$20K Sell
503
-86
-15% -$3.21K ﹤0.01% 867
2020
Q3 		$22K Hold
589
– – 0.01% 772
2020
Q2 		$20K Buy
+589
New +$16.1K 0.01% 726

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Eudaimonia Partners's GMAB Position: Q2 2021 in Review

Eudaimonia Partners sold out of Genmab (GMAB) in Q2 2021, closing a stake of 417 shares — an estimated $14K sold.

Eudaimonia Partners first reported a position in GMAB in Q2 2020 and held it in 4 quarters. The position peaked at $22K in Q3 2020. 212 funds tracked by Wall St. Rank hold GMAB as of Q2 2021.

  • Eudaimonia Partners reported no remaining Genmab position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 417 Genmab shares in Q2 2021, an estimated $14K.
  • Eudaimonia Partners first reported a position in Genmab in Q2 2020 and held it in 4 quarters.
  • Eudaimonia Partners's Genmab position peaked at $22K in Q3 2020.
  • 212 funds tracked by Wall St. Rank held Genmab as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.